CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 0.37×, lower than 95% of its Biotechnology peers (median 5.64×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
291.07MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.16xvs all stocks
52-Week Change
-30.00%vs all stocks
Market Capitalization
291.07MUSDvs all stocks (USD)
Enterprise Value
303.39MUSDvs all stocks (USD)
Forward P/E
-1.17xvs Biotechnology peers
Enterprise to EBITDA
-14.18xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-67.45%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
9.04MUSDvs all stocks (USD)
Net Income (TTM)
-40.28MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-17.98MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-4.85MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · May 31, 2025Operating Income
9.66MUSDvs all stocks (USD)
Pre-tax Income
3.75MUSDFY2025 · May 31, 2025Income Tax Expense
0.00USDFY2025 · May 31, 2025Net Income
3.75MUSDFY2025 · May 31, 2025EBIT
8.58MUSDFY2025 · May 31, 2025EBITDA (Income Statement)
9.04MUSDFY2025 · May 31, 2025Research & Development
-16.92MUSDFY2025 · May 31, 2025Selling, General & Administrative
7.26MUSDFY2025 · May 31, 2025Non-operating Interest Income
565.00KUSDFY2025 · May 31, 2025Non-operating Interest Expense
4.83MUSDFY2025 · May 31, 2025EPS (Basic)
0.00USDFY2025 · May 31, 2025EPS (Diluted)
0.00USDFY2025 · May 31, 2025Basic Shares Outstanding
1.21BSharesFY2025 · May 31, 2025Diluted Shares Outstanding
1.21BSharesFY2025 · May 31, 2025Net Income from Continuing Operations
3.75MUSDFY2025 · May 31, 2025Operating Cash Flow
5.38MUSDFY2025 · May 31, 2025Cash & Cash Equivalents (End of Period)
11.90MUSDFY2025 · May 31, 2025Interest Paid
25.00KUSDFY2025 · May 31, 2025Starting Profit (CF Statement)
3.75MUSDFY2025 · May 31, 2025Depreciation & Amortization
18.00KUSDFY2025 · May 31, 2025Stock-based Compensation
1.61MUSDFY2025 · May 31, 2025Long-term Debt Payments
-710.00KUSDFY2025 · May 31, 2025Net Short-term Debt Issuance
-710.00KUSDFY2025 · May 31, 2025Net Financing Cash Flow
-1.42MUSDFY2025 · May 31, 2025Shares Outstanding
1.36BSharesUpdated Jul 18, 2026Float Shares
1.37BSharesUpdated Jul 18, 2026% Held by Insiders
0.01%vs all stocks
% Held by Institutions
0.02%vs all stocks
Total Cash (MRQ)
15.65MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0110USDUpdated Jul 18, 2026Total Debt (MRQ)
28.82MUSDvs all stocks (USD)
Current Ratio (MRQ)
0.3660xvs Biotechnology peers
Book Value per Share (MRQ)
-0.0770USDUpdated Jul 18, 2026Total Assets
18.05MUSDvs all stocks (USD)
Total Current Assets
17.88MUSDFY2025 · May 31, 2025Total Liabilities
114.09MUSDFY2025 · May 31, 2025Total Non-current Assets
169.00KUSDFY2025 · May 31, 2025Total Non-current Liabilities
43.57MUSDFY2025 · May 31, 2025Total Current Liabilities
70.52MUSDFY2025 · May 31, 2025Cash
11.90MUSDFY2025 · May 31, 2025Cash & Cash Equivalents
11.90MUSDFY2025 · May 31, 2025Accounts Payable
14.69MUSDFY2025 · May 31, 2025Short-term Debt
27.34MUSDFY2025 · May 31, 2025Other Current Liabilities
145.00KUSDFY2025 · May 31, 2025Long-term Debt
0.00USDFY2025 · May 31, 2025Other Non-current Liabilities
43.57MUSDFY2025 · May 31, 2025Common Stock (Book)
1.25MUSDFY2025 · May 31, 2025Retained Earnings
-887.79MUSDFY2025 · May 31, 2025Total Shareholders' Equity
-96.04MUSDvs all stocks (USD)
Treasury Stock
0.00USDFY2025 · May 31, 202552-Week Low
0.2100USDUpdated Jul 18, 202652-Week High
0.4000USDUpdated Jul 18, 202652-Week Change
-30.00%vs all stocks
Beta
1.16xvs all stocks
50-Day MA
0.2846USDUpdated Jul 18, 2026200-Day MA
0.2783USDUpdated Jul 18, 2026Avg 10-Day Volume
1.57MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.83MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.0400USDUpdated Jul 18, 2026Other Income / Expense
-445.00KUSDFY2025 · May 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.37×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.37Industry median: 5.64Industry P5: 1.06Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Cutia Therapeutics Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventage Lab Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lineage Cell Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Hile Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anhui Huangshan Capsule Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
Dirui Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule